Hybrid dextran/fibronectin nanogels for brain-targeted mitophagy inducer delivery to alleviate neuroinflammation and neuronal loss of Parkinson's disease.
AI interpretation is pending for this paper.
What the AI sees
Not AI summarized yet.
Research significance
Pending deeper interpretation.
Source abstract
Parkinson's disease (PD) is characterized by progressive dopaminergic neuron loss, chronic neuroinflammation, and α-synuclein aggregation. Blood-brain barrier (BBB)-penetrable, dual-target nanomedicines for microglial inflammation and neuronal degeneration remain challenging. In this study, we fabricated a brain-targeted, pH- and reactive oxygen species (ROS)-responsive nanogel (NG) platform using dextran (Dex) as the main polysaccharide backbone, crosslinked with inflammation-targeting fibronectin (FN), and loaded with neuroprotective quercetin (Que). Dex-FN/Que NGs exhibited a uniform spherical morphology with an average diameter of 187 nm, favorable colloidal stability, and stimuli-triggered drug release behavior. Abundant hydroxyl groups on Dex enabled efficient BBB penetration, while FN mediated integrin-dependent internalization in microglia and neurons. These NGs suppressed the nuclear factor-kappa B (NF-κB) signaling pathway, scavenged ROS, promoted favorable microglial polarization, and balanced oxidative stress. Meanwhile, mitophagy flux activated by the NGs in neurons exerted strong neuroprotection effect. In a mouse model of PD, Dex-FN/Que NGs effectively crossed the BBB and accumulated in injured brain regions, significantly protecting dopaminergic neurons, improving motor function, and relieving depressive-like behaviors. Therapeutic benefits arose from normalized microglial polarization, reduced oxidative stress, and inhibited neuronal ferroptosis. This Dex-based stimuli-responsive nanoplatform provides a promising brain-targeted strategy for the treatment of PD and other neurological disorders.